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Survival for pancreatic ductal adenocarcinoma is low and the role of adjuvant therapy remains contro-
versial, with the European studies indicating survival beneﬁt of chemotherapy over chemoradiation,
whereas the American reports indicate an undoubted beneﬁt with chemoradiation. Whatever is the
mode of adjuvant care, two things are obvious in the management of this disease: surgery is
the mainstay of treatment and a complete resection is the only hope of cure. Secondly, irrespective of the
adjuvant treatment modality, survival advantage is limited and ﬁve-year survival has failed to reach that
of other malignancies. The mixed results obtained from the various adjuvant therapy trials indicate that
a uniform protocol is yet to be reached. A milestone is said to have been reached when a treatment or
a treatment modality revolutionizes the outcome of a disease. As of now the adjuvant treatment in
pancreatic adenocarcinoma is still evolving. Maybe a fresh look is needed at the biological aspect of the
disease to add a new thought in its management, as has happened with other human malignancies.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Despite the progress made in terms of aggressive loco-regional
therapy, survival data in pancreatic adenocarcinoma have not
signiﬁcantly improved in the last 25 years. The 5-year survival rate
following complete resection is 25e30% for node-negative and 10%
for node-positive cancers.1 Complete surgical resection of the
tumor remains the only chance of cure but a true radical surgery is
actually achievable in less than 20% of cases.2 The high risk of local
and systemic recurrence as well as an overall poor survival is the
rationale for the use of adjuvant therapy in this cancer.
In the late 1970s and early 1980s, a trial conducted by the
Gastrointestinal Tumor Study Group (GITSG) demonstrated a deﬁ-
nite survival advantage with adjuvant chemoradiotherapy (CRT) in
patients with resected pancreatic cancer.3 Unfortunately, the study
population was too small (n ¼ 43) for any convincing conclusion
and it was unclear whether the survival advantage was due to the
combination of CRT and maintenance chemotherapy or to any one
of these. This was followed by a major trial by the Johns Hopkins
Hospital group4 in which the outcome of patients undergoing
resection only for pancreatic adenocarcinoma was compared with
those who were offered adjuvant CRT following surgery. The study
concluded that addition of adjuvant CRT signiﬁcantly improved
survival after pancreaticoduodenectomy (19.5 versus 13.5 months).: þ91 542 2368163.
ciates Ltd. Published by Elsevier LtSubsequently two large-scale randomized controlled trials
(RCTs) in Europe however failed to conﬁrm a signiﬁcant beneﬁt of
adjuvant CRT over resection alone. The European Organization for
Research and Treatment of Cancer (EORTC) study did not show any
signiﬁcant beneﬁt of adjuvant CRT over surgery alone although
a trend in favor of CRT was suggested.5 There was no reduction of
loco-regional recurrence in either group or the 2-year survival
estimate was 10% higher in the chemoradiation group. It concluded
no overall beneﬁt of adjuvant CRT over surgery alone. Technically
however, the study is considered ﬂawed and underpowered. The
second multicenter trial by the European Study Group for Pancre-
atic Cancer (ESPAC-1) suggested a detrimental effect on survival
with adjuvant chemoradiotherapy but not with chemotherapy or
surgery alone.6 Those who received CRT had an estimated 5-year
survival rate of 10% compared to 20% among those who did not and
21% among those who received chemotherapy as opposed to 8%
among those who did not. The beneﬁt achieved by the use of
chemotherapy in the ESPAC-1 trial was in contrast to the results of 2
RCTs from Japan,7,8 which did not suggest prolonged beneﬁcial
effect with 5-FU-based combinations. Interestingly, a meta-analysis
of 5 RCTs of adjuvant therapy in pancreatic cancer reported a 25%
signiﬁcant reduction in death risk with chemotherapy as adjuvant
treatment.9 There was no signiﬁcant difference in the 2- and 5-year
survival between those who received CRT and those who did not.
However CRT was more effective than chemotherapy in patients
with positive resection margins. It concluded that chemotherapyd. All rights reserved.
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However very recently a large collaborative study from the Mayo
Clinic and the Johns Hopkins hospital demonstrated a signiﬁcant
survival beneﬁt in those receiving adjuvant CRT compared to
surgery alone (21.1 versus 15.5 months). Compared to surgery
alone, adjuvant CRT improved survival by 33% after stratiﬁcation by
age, margin, node and T-stage status. Overall survival at 2- and 5-
years was also superior with adjuvant CRT.10
Themixed results with the use of 5-FU-based chemotherapy gave
way to the introduction of gemcitabine in 1996 as a probable better
adjuvant regimen. It was considered a major step in the adjuvant
treatment of pancreatic cancer, which is still currently practiced as
the standard of care. After an initial trial had demonstrated survival
advantage with gemcitabine,11 multicentric randomized trials like
the CONKO-00112 and RTOG-970413 followed. Gemcitabine was
found to signiﬁcantly delay the development of recurrent disease
after complete resection of pancreatic cancer. Subgroup analyses also
demonstrated a signiﬁcant disease-free survival in patients with
either R0 or R1 resection. It was found to be superior to 5-FU-based
regimen in terms of improved survival.13 The most recent ESPAC-
3(v2) trial,14 which recruited 1088 patients from 16 countries,
demonstrated no signiﬁcant difference between gemcitabine and 5-
FUplus leucovorin on the treatment outcome and survival inpatients
who had undergone R0 or R1 resections for pancreatic cancers.
Despite heterogeneity, subgroup analysis proved no signiﬁcant
difference in the effect of treatment according to the R-status.
Since surgical resection of localized disease remains the only
hope for cure and since most of the pancreatic tumors are detected
late, chance for a curative resection is available to a minor subset of
patients with early detection. Moreover, even if it appears to be
potentially curative on preoperative imaging, getting a reliable
retroperitoneal margin may not always be feasible during surgery.
In this setting, the option of neoadjuvant treatment has been
considered to downstage the disease and to combine it with an
oncological resection for better local control and survival. In a case
control study, Ishikawa et al. in 199415 observed that downstaging
of pancreatic cancers with neoadjuvant CRT allows oncological
resection. In another trial by Evans et al., 28 patients with adeno-
carcinoma of the pancreatic head received preoperative chemo-
radiation and continuous infusion of 5-FU.16 Four to ﬁveweeks later
the patients were restaged. Of the 23 patients who underwent
laparotomy, curative pancreaticoduodenectomy could be done in
17 patients. Hoffman et al.17 recruited 53 patients who received
preoperative continuous infusion 5-FU, mitomycin-C and radiation
therapy. Out of 53 patients, 24 showed downstaging and under-
went resection with a median survival of 15.7 months compared
with 9.7 months for the entire group.
In response to thequestionofwhetherneoadjuvantCRT improved
survival, only a few studies have shown highmedian survival rates of
two years or more following neoadjuvant treatment. In a study by
Snady et al.,18 68 patients received neoadjuvant treatment with
concurrent split course EBRT and 5-FU, streptozotocin and cisplatin.
Of these, 20 patients (29%) who underwent resection achieved
a median survival rate of 32months as compared to 23.6 months for
the entire group. Mehta et al.19 reported a median survival of 30
monthswith neoadjuvant treatment but only in nine patients. Pisters
et al.20 used preoperative rapid fractionation chemoradiationwith 5-
FU for 2 weeks and concurrent external beam radiation therapy
(EBRT)with 30Gy for 2weeks in 35 patients. Following resection, the
patients received intraoperative radiation therapy (IORT). The
median survival rate was 25 months and the 3-year actuarial overall
survival rate was 23%. In another study,21 a median survival of 25
months was observed in the resected group (21 of 34 patients)
following neoadjuvant twice-weekly gemcitabine (50 mg/m2) and
EBRT (50.4 Gy) in locally advanced potentially resectable pancreaticcancers. Calvo et al.22 evaluated neoadjuvant tegafur (1200 mg/day)
with concurrent EBRT in potentially resectable pancreatic cancers in
15 patients and concluded that median survival was signiﬁcantly
better in the resected group compared to those not undergoing
resection (23 versus 8 months). Unfortunately the beneﬁts of neo-
adjuvant CRT in improving median survival have been reported
mostly from small, single institution-based studiesmost ofwhich are
non-randomized and contain a heterogeneous disease population.
Preoperative chemoradiation for potentially resectable pancre-
atic cancer has several advantages. It eliminates the delay of adju-
vant treatment from postoperative recovery and could spare
unnecessary surgery for patients with metastatic disease evident
on restaging after neoadjuvant therapy. During neoadjuvant
therapy, disease progression occurs in 15e25% of the patients, with
the appearance of liver metastases and/or peritoneal carcinosis.23
Downstaging after neoadjuvant treatment may theoretically
increase the likelihood of a negative surgical margin. It could
prevent tumor cell implantation and dissemination during surgery
but this has not been proven. In recent controlled clinical trials
comparing historical and prospective control groups, the frequency
of downstaging was observed to be between 13% and 45%.23 Neo-
adjuvant chemoradiation resulted in a decrease in the frequency of
cancer-positive margins and oncological resection after neo-
adjuvant chemoradiation resulted in a median survival between 15
and 32 months. Moreover after neoadjuvant treatment no increase
in postoperative complications has been reported. Unfortunately,
many reports of neoadjuvant therapy for pancreatic cancer have
included heterogeneous patient populations, enrolling patients
with resectable, marginally resectable and locally advanced
pancreatic cancer.17,19,21,24e26 This confounds reports of resection
rates and complicates comparison with other studies.
In the case of locally advanced pancreatic cancer, the aim of
preoperative chemoradiation has been to downstage the loco-
regional disease and to facilitate surgical resection, importantly R0
resection. Locally advanced pancreatic cancer describes pancreatic
cancer without evidence of distant metastasis but locally unre-
sectable due to tumor encasement of major vessels such as celiac
and superior mesenteric arteries or the portal vein. Downstaging in
this group of locally advanced pancreatic cancer leads to a separa-
tion between tumor and vessel wall and to an increase of resection
rates between 29% and 80%, and a survival beneﬁt after oncological
resection.23 Although local control rates have been improved by
radiation therapy, systemic failure remains a major obstacle in
improving the long-term survival. Due to high rates of distant
metastasis and poor overall survival rates, the value of secondary
resection after conversion of unresectable disease to resectable
disease is questioned in the treatment of this subgroup. Since this
issue has not been addressed in larger studies, the question remains
controversial. The available smaller phase I and II studies report an
increase in the median survival following secondary resection
compared to all patients. But as these are small and single insti-
tution-based studies, selection bias cannot be ruled out. Further,
interpretation of these data is difﬁcult because of different criteria
for resectability. A specialist pancreatic cancer surgery team can
often resect what is considered by another team to be unresectable
locally advanced disease, indicating that primary resectability may
have been deﬁned differently.27 In cases where no downstaging
with secondary resectability can be achieved, median survival is
only around 10 months and 5-year survival is near zero. However,
in this subset of patients signiﬁcant palliative beneﬁt can be ach-
ieved by CRT. Complete pain relief can be obtained in as many as
50e80% of patients, as well as some improvement in wasting,
obstructive symptoms, performance status, and anorexia.28
As early as in 1983, it was thought that adding IORT to the
protocol to deliver much higher doses of radiation to the
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this technique was demonstrated on a patient with locally advanced
pancreatic cancer, who survived disease-free for more than 19
months after total pancreatectomywith portal resection followed by
IORT to the tumor bed and regional lymph nodes.29 A subsequent
RCT, which compared the outcome of IORT (20 Gy) or observation or
EBRT (50 Gy) showed signiﬁcant improvement of local control and
a better overall survival rate in the IORTgroup (18 versus 12months).
Despite this improvement in loco-regional control, no difference in
the disease-free survival was observed.30 Several other studies have
described favorable effects of IORT in pancreatic cancer,31e33 but are
limited with regard to any clear recommendation. It has also been
suggested that neoadjuvant CRT may actually improve the effects of
IORT in terms of local control and overall survival.34,35 While
metastasis still remains the main challenge for this disease, the
improvement of local control by adding IORTmay have an impact on
the survival of patients due to a lesser tendency for disease spread.
Clearly, a more efﬁcient multimodality treatment strategy is needed
to control micrometastasis and to select patients who could beneﬁt
by surgery and local therapies.
The treatment of pancreatic adenocarcinoma has witnessed the
use of different chemotherapy regimens, chemotherapy alone or in
combination with radiotherapy in different doses, techniques of
delivery and sequence of usage. Overall, these treatments are still
evolving. Although adjuvant chemoradiation has achieved local
control in mixed reports, long-term survival advantage has eluded
the clinician for the past three decades. The beneﬁt has been only in
statistical terms, and the 5-year survival rate still remains dismally
low. This, coupled with the morbidity of surgery and chemo-
radiation, raises the important question of whether or not we have
reached a milestone in the treatment of this disease. Perhaps a shift
of focus is needed toward the biological behavior of the disease
utilizing a better understanding of tumor biology with regard to
cellular/genetic function coupled to a strategic implementation of
existing therapeutic protocols in the future.
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